Please login to the form below

Not currently logged in
Email:
Password:

GSK joint venture for flu vaccine

A joint venture aimed at developing flu vaccines in China has been announced by GlaxoSmithKline

GSK will combine forces with Shenzhen Neptunus, taking a 40 per cent stake for £21m initially, with the prospect of increasing to majority control within two years.

The deal is another example of GSK pushing into emerging markets and enables it to enter the potentially large Chinese market for vaccines, where the Chinese preference has been to purchase vaccines from domestic manufacturers.

It will give the company access to Chinese antigens for flu, and allow them to add GSK's own "adjuvant" to increase the efficacy and efficiency of the vaccine.

This is the first time GSK has created a joint venture in vaccines, and the company is likely to make similar moves in other emerging markets in the future.

GSK is expected to provide about £18m in cash towards the joint venture in the first stage, the remaining £3m being supplied in the form of equipment. It will produce vaccines for China, Hong Kong and Macau.

The deal is expected to complete during the fourth quarter this year.

In a separate event, GSK chief executive, Andrew Witty, attended the opening of the company's £365m factory in Singapore this week, which will produce its pneumococcal vaccine. Singapore prime minister, Lee Hsien Loong, said the city-state was proud to be part of the venture, which could save three million lives per year. The plant could employ up to 1,100 workers, setting up production processes and quality controls. Commercial production is expected to start in 2011.

10th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics